tiprankstipranks
Trending News
More News >

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics (ACRSResearch Report). The associated price target remains the same with $16.00.

Don’t Miss TipRanks’ Half-Year Sale

Ram Selvaraju has given his Buy rating due to a combination of factors including the promising potential of Aclaris Therapeutics’ investigational therapies and the strategic progression of their clinical trials. The initiation of the Phase 1a/1b program for ATI-052, a bispecific antibody targeting TSLP and IL-4R, is a significant step forward. This therapy is designed to enhance efficacy by simultaneously inhibiting two pathways involved in immune-modulated diseases, which could potentially offer superior treatment options compared to traditional monoclonal antibodies.
Moreover, Aclaris has multiple ongoing pipeline programs with near- and medium-term catalysts that could drive future growth. The advancement of bosakitug into a Phase 2 trial for atopic dermatitis and the ongoing Phase 2a trial of ATI-2138 in moderate-to-severe atopic dermatitis patients demonstrate the company’s robust development strategy. Additionally, preclinical work on next-generation ITK inhibitors and bispecifics further supports the long-term potential of Aclaris’ pipeline. These factors collectively underpin Selvaraju’s confidence in the company’s prospects, leading to a reiterated Buy rating and a 12-month price target of $16.

Disclaimer & DisclosureReport an Issue

1